82 research outputs found
Emericellopsis maritima and Purpureocillium lilacinum Marine Fungi as a Source of Functional Fractions with Antioxidant and Antitumor Potential in Colorectal Cancer: A Preliminary Study
This work was co-financed by the 2014–2020 ERDF Operational Programme and by the
Department of Economy, Knowledge, and Business of the University of the Regional Government of
Andalusia (project reference: FEDER-UCA18-105749).The following supporting information can be downloaded at
https://www.mdpi.com/article/10.3390/jmse11102024/s1The marine environment is a promising source of natural products with possible pharmacological applications. In this sense, marine microorganisms, especially marine fungi, can produce bioactive compounds with various therapeutic properties. Colorectal cancer (CRC) represents a major health problem worldwide, since the treatments used to date are not capable of improving patient survival; that is why natural compounds from marine fungi offer a promising alternative. This study focused on evaluating the antitumor and antioxidant activity of fractions derived from the marine fungi E. maritima and P. lilacinum in two CRC cell lines T84 and SW480. Fractions Fr-EM6, Fr-EM7, Fr-EM8 and Fr-PLMOH-3 demonstrated potent cytotoxic activity in tested CRC cell lines with no activity in the non-tumor line. In particular, the Fr-PLMOH-3 fraction from P. lilacinum showed significant antiproliferative effects on T84 and SW480 cell lines and exhibited a greater cytotoxic effect on cancer stem cells compared to tumor cells. Furthermore, the Fr-EM8 fraction from E. maritima demonstrated a strong antioxidant capacity. These findings highlight the potential of compounds of marine origin as effective and selective antitumor agents for the treatment of CRC. Further studies are needed to explore the underlying mechanisms and potential clinical applications of these bioactive fractions and compounds.014–2020 ERDF Operational ProgrammeRegional Government of
Andalusia FEDER-UCA18-10574
Double inferior vena cava-an important anatomical variant in retroperitoneal surgery
University of
Granada/CBU
Electrospraying as a Technique for the Controlled Synthesis of Biocompatible PLGA@Ag2S and PLGA@Ag2S@SPION Nanocarriers with Drug Release Capability
This research was funded "Atraccion de Talento" fellowship from the Comunidad de Madrid, grant number 2018-T1/IND-10736; the Universidad Complutense de Madrid, grant number UCM-Santander (CT63/19-CT64/19); the Junta de Andalucia (P18-HO-3882, P20_00540, A-CTS666-UGR20-FEDER); and Instituto de Salud Carlos III (PI19/01478-FEDER). P.G. acknowledges financial support from the Spanish government (MICIU) through the Ramon y Cajal research program (RyC2019-028414-I). M.F. thanks the Comunidad Autonoma de Madrid for research project No. 2017T1/BIO-4992 ("Atraccion de Talento" Action) cofunded by Universidad Complutense de Madrid. M.F. is grateful to Instituto de Salud Carlos III (ISCIII) for project No DTS20/00109 (AES-ISCIII). M.F. and L.L.C would also like to thank Comunidad de Madrid for the predoctoral grant IND2020/BIO-17523.Ag2S nanoparticles are near-infrared (NIR) probes providing emission in a specific spectral
range (~1200 nm), and superparamagnetic iron oxide nanoparticles (SPION) are colloidal systems able
to respond to an external magnetic field. A disadvantage of Ag2S NPs is the attenuated luminescent
properties are reduced in aqueous media and human fluids. Concerning SPION, the main drawback is
the generation of undesirable clusters that reduce particle stability. Here, we fabricate biocompatible
hybrid nanosystems combining Ag2S NPs and SPION by the electrospraying technique for drug
delivery purposes. These nanostructures are composed of poly(lactic-co-glycolic acid) (PLGA) as
the polymeric matrix in connection with both Ag2S NPs and SPIONs. Initially, we fabricate a hybrid
colloidal nanosystem composed of Ag2S NPs in connection with PLGA (PLGA@Ag2S) by three
different routes, showing good photoluminescent (PL) properties with relatively high average decay
times. Then, we incorporate SPIONs, obtaining a PLGA polymeric matrix containing both Ag2S
NPs and SPION (PLGA@Ag2S@SPION). Interestingly, in this hybrid system, the location of Ag2S
NPs and SPIONs depends on the synthesis route performed during electrospraying. After a detailed
characterization, we demonstrate the encapsulation and release capabilities, obtaining the kinetic
release using a model chemotherapeutic drug (maslinic acid). Finally, we perform in vitro cytotoxicity
assays using drug-loaded hybrid systems against several tumor cell lines.Comunidad de Madrid 2018-T1/IND-10736
IND2020/BIO-17523Universidad Complutense de Madrid CT63/19-CT64/19Junta de Andalucia P18-HO-3882
P20_00540
A-CTS666-UGR20-FEDERInstituto de Salud Carlos III
European Commission PI19/01478-FEDER
DTS20/00109Spanish government (MICIU) through the Ramon y Cajal research program RyC2019-028414-IComunidad de Madrid 2017T1/BIO-499
Evaluation of Novel Doxorubicin-Loaded Magnetic Wax Nanocomposite Vehicles as Cancer Combinatorial Therapy Agents
The development of nanotechnology-based solutions for cancer at a preclinical level
advances at an astounding pace. So far, clinical translation of these new developments has not been
able to keep the pace due to a range of different reasons. One of them is the mismatch between
in vitro and in vivo results coming from the expected difference in complexity. To overcome this
problem, extensive characterisation using advanced in vitro models can lead to stronger preliminary
data to face in vivo tests. Here, a comprehensive in vitro validation of a combinatorial therapy
nanoformulation against solid tumours is presented. The information extracted from the different
in vitro models highlights the importance of advanced 3D models to fully understand the potential
of this type of complex drugs."Local specific treatment of triple-negative-breast-cancer through externally triggered target-less drug carriers" project - FCT
031142ERDF through NORTE2020Portuguese Foundation for Science and Technology
UTAP-EXPL/NTec/0038/20172014-2020 INTERREG Cooperation Programme Spain-Portugal (POCTEP)
0624_2IQBIONEURO_6_
Bengamide Analogues Show A Potent Antitumor Activity against Colon Cancer Cells: A Preliminary Study
C.P.A., I.C.S. and B.G.P. thank Ministerio de Educación, Cultura y Deporte for their predoctoral
fellowships (FPI and FPU programmes). The authors thank the Center of Scientific Instrumentation personnel of
the University of Granada for technical assistance, and the Mass Spectrometry and NMR facilities of the University
of Málaga for exact mass and NMR spectroscopic assistances, respectively.The limited success and side effects of the current chemotherapeutic strategies against
colorectal cancer (CRC), the third most common cancer worldwide, demand an assay with new drugs.
The prominent antitumor activities displayed by the bengamides (Ben), a family of natural products
isolated from marine sponges of the Jaspidae family, were explored and investigated as a new option
to improve CRC treatment. To this end, two potent bengamide analogues, Ben I (5) and Ben V (10),
were selected for this study, for which they were synthesized according to a new synthetic strategy
recently developed in our laboratories. Their antitumor effects were analyzed in human and mouse
colon cell lines, using cell cycle analysis and antiproliferative assays. In addition, the toxicity of the
selected analogues was tested in human blood cells. These biological studies revealed that Ben I
and V produced a significant decrease in CRC cell proliferation and induced a significant cell cycle
alteration with a greater antiproliferative effect on tumor cell lines than normal cells. Interestingly,
no toxicity effects were detected in blood cells for both compounds. All these biological results render
the bengamide analogues Ben I and Ben V as promising antitumoral agents for the treatment of CRC.MINECO
BIO2014-56092-R
RTI2018-098296-BI00
CTQ2016-76311European Union (EU)
BIO2014-56092-R
RTI2018-098296-BI00
CTQ2016-76311
P12-CTS-1507Andalusian Government
P12-CTS-1507
BIO-267
CTS-107Instituto de Salud Carlos III
European Union (EU)
PI19/01478Junta de Andalucia
PI-0102-201
Synthetic Circular miR-21 Sponge as Tool for Lung Cancer Treatment
This work was funded by the CTS-107 Group. This work was also partially supported by a grant from the Instituto de Salud Carlos III (ISCIII) (project PI19/01478) (FEDER).Lung cancer is the most common cancer in the world and several miRNAs are associated
with it. MiRNA sponges are presented as tools to inhibit miRNAs. We designed a system to capture
miRNAs based on circular RNAs (circRNA). To demonstrate its usefulness, we chose miR-21, which is
upregulated and implicated in lung cancer. We constructed a miR-21 sponge and inserted it into
a vector that facilitates circular RNA production (Circ-21) to study its effect on growth, colony
formation, and migration in lung cancer cell lines and multicellular tumor spheroids (MTS). Circ-21
induced a significant and time-dependent decrease in the growth of A549 and LL2 cells, but not
in L132 cells. Furthermore, A549 and LL2 cells transfected with Circ-21 showed a lower number
of colonies and migration than L132. Similar findings were seen in A549 and LL2 Circ-21 MTS,
which showed a significant decrease in volume growth, but not in L132 Circ-21 MTS. Based on this,
the miR-21 circular sponge may suppress the processes of tumorigenesis and progression. Therefore,
our system based on circular sponges seems to be effective, as a tool for the capture of other miRNAs.Instituto de Salud Carlos III
European Commission PI19/01478CTS-10
Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis
Junta de Andalucía, Grant/Award Numbers:
102C2000004, UAL2020-AGR-B1781,
P20_01041; Gobierno de España,
Grant/Award Numbers: PDC2021–
121248-I00, PLEC2021–007774; Instituto de
Salud Carlos III (ISCIII), Grant/Award Number:
PI19/01478; CTS-107 and FQM-376 groupsWe describe the use of nuclear magnetic resonance metabolomics to analyze blood
serum samples from healthy individuals (n = 26) and those with metastatic colorectal
cancer (CRC; n = 57). The assessment, employing both linear and nonlinear multivari-
ate data analysis techniques, revealed specific metabolite changes associated with
metastatic CRC, including increased levels of lactate, glutamate, and pyruvate, and
decreased levels of certain amino acids and total fatty acids. Biomarker ratios such as
glutamate-to-glutamine and pyruvate-to-alanine were also found to be related to
CRC. The study also found that glutamate was linked to progression-free survival and
that both glutamate and 3-hydroxybutyrate were risk factors for metastatic CRC.
Additionally, gas chromatography coupled to flame-ionization detection was utilized
to analyze the fatty acid profile and pathway analysis was performed on the profiled
metabolites to understand the metabolic processes involved in CRC. A correlation
was also found between the presence of certain metabolites in the blood of CRC
patients and certain clinical features.Junta de Andalucia
102C2000004,
UAL2020-AGR-B1781,
P20_01041Gobierno de España
MCIN/AEI/10.13039/501100011033/Unión Europea “Next GenerationEU”/PRTR (PDC2021–121248-I00 and PLEC2021–007774)Instituto
de Salud Carlos III (ISCIII) (PI19/01478) (FEDER)CTS-107FQM-37
Tissue Specific Promoters in Colorectal Cancer
Colorectal carcinoma is the third most prevalent cancer in the world. In the most advanced stages, the use of chemotherapy induces a poor response and is usually accompanied by other tissue damage. Significant progress based on suicide gene therapy has demonstrated that it may potentiate the classical cytotoxic effects in colorectal cancer. The inconvenience still rests with the targeting and the specificity efficiency. The main target of gene therapy is to achieve an effective vehicle to hand over therapeutic genes safely into specific cells. One possibility is the use of tumor-specific promoters overexpressed in cancers. They could induce a specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several promoters have been assayed into direct suicide genes to cancer cells. This review discusses the current status of specific tumor-promoters and their great potential in colorectal carcinoma treatment.This research was funded by FEDER, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I), and Instituto de Salud Carlos III (FIS), through projects PI11/01862 and PI11/0257
Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but due
to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering
diagnostic biomarkers for early detection is crucial for improving clinical outcomes. Metabolomics
has become a powerful technology for biomarker discovery, and several metabolomic-based panels
have been proposed for PDAC diagnosis, but these advances have not yet been translated into the
clinic. Therefore, this review focused on summarizing metabolites identified for the early diagnosis
of PDAC in the last five years. Bibliographic searches were performed in the PubMed, Scopus and
WOS databases, using the terms “Biomarkers, Tumor”, “Pancreatic Neoplasms”, “Early Diagnosis”,
“Metabolomics” and “Lipidome” (January 2018–March 2023), and resulted in the selection of fourteen
original studies that compared PDAC patients with subjects with other pancreatic diseases. These
investigations showed amino acid and lipid metabolic pathways as the most commonly altered,
reflecting their potential for biomarker research. Furthermore, other relevant metabolites such as
glucose and lactate were detected in the pancreas tissue and body fluids from PDAC patients. Our
results suggest that the use of metabolomics remains a robust approach to improve the early diagnosis
of PDAC. However, these studies showed heterogeneity with respect to the metabolomics techniques
used and further studies will be needed to validate the clinical utility of these biomarkersB-TIC-414-UGR18 (Junta deAndalucía 2020) (FEDER
Chronic pancreatitis: analysis of disease progression factors
Background: Alcohol and tobacco are important risk factors for chronic pancreatitis (CP). Aim: To analyze the effect of etiological factors such as tobacco and alcohol and pancreatic enzyme replacement therapy (PERT) in the progression of CP. Material and Methods: Patients with a diagnosis of CP were recruited and grouped according to variables such as tobacco, alcohol and PERT. They were followed for 18 months. Subsequently, different variables and analytical parameters involved in the progression of the disease were analyzed. Results: A total of 50 patients diagnosed with CP were included. Of these, 28 patients underwent PERT, 39 were smokers and 33 were alcohol users. Compared with patients without PERT, those with PERT had a higher proportion of diabetes (64 and 32%, respectively), had a higher need for endoscopic treatment (25 and 0%, respectively) and a normal body mass index (71 and 27.3%, respectively. The smokers had higher calcium levels and increased lymphocytosis and leukocytosis. The alcohol consumption group had a higher mean age (p = 0.04) Conclusions: PERT may improve the nutritional status but does not reduce the need for endoscopic or surgical treatment. Smoking and alcohol consumption favored the progression of CP. Also, smoking induced a pro-inflammatory state.Fondos FEDER,
A-CTS-436-UGR2
- …